- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05333705
Donor Immune Cell Therapy for Acute Myeloid Leukemia
Trial of Donor Immune Cell Therapy for Acute Myeloid Leukemia.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Primary end point:
To determine the rate of overall survival at 2 years of Interventional cohort
Secondary end point:
To determine the cumulative incidence of relapse at 2 years. To determine the rate of disease-free survival at 2 years. Describe the safety and toxicity of donor NK cell infusion.
Study Design:
This study is a phase I clinical trial. 15 eligible AML patients will be enrolled sequentially to receive detached NK cells product during induction or consolidation therapy. Refractory or relapsed patients and patients who achieved complete remission (CR) after induction therapy are included. They will receive anthracycline-based chemotherapy according to NCCN guidelines. At the same time, Cultured NK cells will be infused into patients after chemotherapy. Anti-allergic therapy and prophylaxis of graft versus host disease (GVHD) will be given before infusion. Treatment effect will be measured and adverse effect will be treated and documented after intervention.
Studietype
Inschrijving (Verwacht)
Fase
- Fase 1
Contacten en locaties
Studiecontact
- Naam: huaiyu Wang, doctor
- Telefoonnummer: 0086-18991232410
- E-mail: whymed@126.com
Studie Contact Back-up
- Naam: sha Gong, doctor
- Telefoonnummer: 0086-18710720955
- E-mail: 314621649@qq.com
Studie Locaties
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710016
- Werving
- First Affiliated Hospital of Xian Jiaotong University
-
Contact:
- Huaiyu Wang, Doctor
- Telefoonnummer: 0086-15809207527
- E-mail: whymed@126.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Patients must have been diagnosed as acute myeloid leukemia in accordance with "Chinese Diagnosis and Treatment Guidelines of AML". Those who achieved CR after chemotherapy are mainly included. Refractory/relapsed AML can also be enrolled.
- Patients with normal heart function (ejection fraction ≥ 50%), normal liver function(ALT and AST ≤ 2.5 times the upper limit of normal value, bilirubin ≤ 2 times the upper limit of normal value) and normal renal function with blood creatinine ≤ 3.0 mg/dL (≤ 260 µmol /L) can be enrolled.
- Patients will be required to sign an informed consent.
Exclusion Criteria:
- Patients with severe infection or other malignant tumors.
- Women during pregnancy or lactation.
- Other patients deemed unsuitable by the investigator.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: immune cell arm
Umbilical cord blood or donated peripheral blood of healthy donors were collected and NK cells were cultured.
NK cell production will be infused after chemotherapy.
|
Umbilical cord blood or donated peripheral blood of healthy donors were collected and NK cells were sorted and cultured.
NK cell production will be infused after chemotherapy
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
hematological response rate
Tijdsspanne: up to 2 years, from treatment begining to death
|
Hematological Complete Remission (HCR): Bone marrow blasts <5%; absence of blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count >1.0x10^9/L; platelet count >100x10^9/L.
|
up to 2 years, from treatment begining to death
|
Overall survival
Tijdsspanne: Up to 2 years after beginning treatment
|
Overall survival (OS) is measured from the date of first infusion of NK cells to the date of death from any cause; patients not known to have died at last follow up are censored on the date they were last known to be alive.
|
Up to 2 years after beginning treatment
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Cumulative incidence of relapse
Tijdsspanne: Up to 2 years after beginning treatment
|
Relapse was defined as the recurrence of above 5%bone marrow blasts and the reappearance of blasts in the blood or the development of extramedullary disease infiltrates at any site.
|
Up to 2 years after beginning treatment
|
Disease free survival (DFS)
Tijdsspanne: Up to 2 years after beginning treatment
|
Disease free survival (DFS) is defined as the time from the date of first infusion of NK cells to the date of relapse or death as a result of any cause.
|
Up to 2 years after beginning treatment
|
Incidence of adverse effects
Tijdsspanne: Up to 2 years after beginning treatment
|
Toxic effects were graded according to the National Cancer Institute's Common Toxicity Criteria.
|
Up to 2 years after beginning treatment
|
Medewerkers en onderzoekers
Onderzoekers
- Studie stoel: huaiyu Wang, doctor, First Affiliated Hospital Xi'an Jiaotong University
Publicaties en nuttige links
Algemene publicaties
- Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K, Urbani E, Negrin RS, Martelli MF, Velardi A. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 1999 Jul 1;94(1):333-9.
- Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, McGlave PB. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005 Apr 15;105(8):3051-7. doi: 10.1182/blood-2004-07-2974. Epub 2005 Jan 4.
- Bachanova V, Cooley S, Defor TE, Verneris MR, Zhang B, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lewis D, Hippen K, McGlave P, Weisdorf DJ, Blazar BR, Miller JS. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood. 2014 Jun 19;123(25):3855-63. doi: 10.1182/blood-2013-10-532531. Epub 2014 Apr 9.
- Curti A, Ruggeri L, Parisi S, Bontadini A, Dan E, Motta MR, Rizzi S, Trabanelli S, Ocadlikova D, Lecciso M, Giudice V, Fruet F, Urbani E, Papayannidis C, Martinelli G, Bandini G, Bonifazi F, Lewis RE, Cavo M, Velardi A, Lemoli RM. Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients. Clin Cancer Res. 2016 Apr 15;22(8):1914-21. doi: 10.1158/1078-0432.CCR-15-1604. Epub 2016 Jan 19.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Verwacht)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- XJYFY-2020N8
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Acute myeloïde leukemie
-
Versailles HospitalWervingCHRONISCHE MYeloGENE LEUKEMIE IN VERSNELDE FASE | CHRONISCHE MYeloGENE LEUKEMIE IN MYELOID BLAST CRISISFrankrijk
Klinische onderzoeken op infusion of natural killer cells
-
University of NebraskaIngetrokken
-
Ottawa Hospital Research InstituteATGen Canada IncVoltooidColorectale kanker | Chirurgie | Perioperatieve zorgCanada
-
Wenxiang WangShanghai Houchao Biotechnology Co., LtdOnbekendNiet-kleincellige longkankerChina
-
Hospital de Clinicas de Porto AlegreOnbekend
-
Minghui ZhangShanghai Public Health Clinical Center; First Hospital of Tsinghua UniversityWervingHepatocellulair carcinoom | Maagkanker | Colorectale kanker | Niet-kleincellige longkankerChina
-
Zhejiang UniversityWervingRefractaire gemetastaseerde colorectale kankerChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)VoltooidRecidiverend medulloblastoom bij kinderen | Recidiverend ependymoom | Recidiverend medulloblastoomVerenigde Staten
-
Brenda Cooper, MDVoltooidWekedelensarcoom | Acute myeloïde leukemie | Hodgkin lymfoom | Acute lymfatische leukemie | Chronische lymfatische leukemie | Non-Hodgkin lymfoom | Chronische myeloïde leukemie | Myelodysplastisch syndroom | Plasmacelmyeloom | Rhabdomyosarcoom | Coloncarcinoom | Adenocarcinoom van het rectum | Myeloproliferatieve... en andere voorwaardenVerenigde Staten
-
Yonsei UniversityVoltooidGevorderde galwegkankerKorea, republiek van
-
The Third Affiliated Hospital of Guangzhou Medical...Hangzhou Cheetah Cell Therapeutics Co., LtdWervingRefractaire gemetastaseerde colorectale kankerChina